From a therapeutic positioning perspective, GLP‐1 receptor agonists such as semaglutide are particularly advantageous for patients with MASH who also suffer from obesity or type 2 diabetes, which is a frequent occurrence. Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.